ALKEM.NS Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (29 bal. 2024 @ 10:00):

Alkem Laboratories Limited, a pharmaceutical company, engages in the development, manufacture, and sale of pharmaceutical and nutraceutical products in India and internationally...

Stats
Šios dienos apimtis	74 786.00
Vidutinė apimtis	257 805
Rinkos kapitalizacija	589.66B
EPS	INR49.76 ( 2024-02-09 )
Kita pelno data	( INR0 ) 2024-05-16
Last Dividend	INR10.00 ( 2023-08-09 )
Next Dividend	INR0 ( N/A )
P/E	37.47
ATR14	INR3.05 (0.06%)

Tūris Koreliacija

Ilgas: -0.11 (neutral)

Trumpas: -0.78 (moderate negative)

Signal:(53.683) Neutral

Alkem Laboratories Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
MASPTOP50.NS	0.902
MAFANG.NS	0.885
BAJAJ-AUTO.NS	0.881
HARIOMPIPE.NS	0.876
MON100.NS	0.869
SETF10GILT.NS	0.868
DATAPATTNS.NS	0.868
MANINDS.NS	0.865
MOGSEC.NS	0.862
GTNTEX.NS	0.861

10 Labiausiai neigiamai susiję koreliacijos
MOHOTAIND.NS	-0.877
ROLTA.NS	-0.865
SECURKLOUD.NS	-0.864
SUMICHEM.NS	-0.861
RUSHIL.NS	-0.852
CLNINDIA.NS	-0.849
BAFNAPH.NS	-0.848
LICI.NS	-0.847
DPSCLTD.NS	-0.846
EASTSILK.NS	-0.841

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Alkem Laboratories Koreliacija - Valiuta/Žaliavos

-0.47
( neutral )

0.13
( neutral )

0.05
( neutral )

-0.56
( weak negative )

-0.15
( neutral )

0.41
( neutral )

Alkem Laboratories Finansinės ataskaitos

Annual	2022
Pajamos:	INR115.99B
Bruto pelnas:	INR66.92B (57.70 %)
EPS:	INR82.31

FY	2022
Pajamos:	INR115.99B
Bruto pelnas:	INR66.92B (57.70 %)
EPS:	INR82.31

FY	2022
Pajamos:	INR105.12B
Bruto pelnas:	INR62.29B (59.25 %)
EPS:	INR137.63

FY	2021
Pajamos:	INR87.47B
Bruto pelnas:	INR51.61B (59.00 %)
EPS:	INR132.57

Financial Reports:

No articles found.

Alkem Laboratories Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
INR4.00 (N/A)	INR0 (N/A)	INR25.00 (N/A)	INR0 (N/A)	INR10.00 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)

Alkem Laboratories Dividend Information - Dividend Junior

Dividend Sustainability Score: 3.90 - low (29.79%) | Divividend Growth Potential Score: 5.50 - Stable (9.99%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	INR9.70	2016-03-18
Last Dividend	INR10.00	2023-08-09
Next Dividend	INR0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	15	--
Total Paid Out	INR177.70	--
Avg. Dividend % Per Year	0.71%	--
Score	2.85	--
Div. Sustainability Score	3.90
Div.Growth Potential Score	5.50
Div. Directional Score	4.70	--

Next Divdend (Est)
(2024-08-08)

INR8.69 Estimate 7.41 %

Dividend Stability

0.30 Very Poor

Dividend Score

2.85

Pay Frequency

Semi-Annually

Yearly Payout

Year	Amount	Yield
2016	INR0	0.00%
2017	INR0	0.00%
2018	INR13.00	0.65%
2019	INR16.00	0.83%
2020	INR25.00	1.20%
2021	INR30.00	1.02%
2022	INR34.00	0.93%
2023	INR35.00	1.17%
2024	INR0	0.00%

Dividend Commentary

The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.

Top 10 dividend Companies for NSE

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend
RADICO.NS	Dividend Junior	2023-09-14	Annually	22	0.24%
KHAICHEM.NS	No Dividend Player	2023-07-21	Annually	5	0.32%
EMAMIPAP.NS	Dividend Junior	2023-09-05	Annually	3	0.56%
AJANTPHARM.NS	Dividend Junior	2023-08-04	Annually	23	0.57%
SUNTV.NS	Dividend Knight	2023-08-22	Quarterly	19	1.94%
NAVNETEDUL.NS	Dividend Junior	2023-08-07	Annually	22	1.10%
HPIL.NS	Dividend Junior	2023-09-29	Annually	5	0.89%
CARERATING.NS	Dividend Knight	2023-07-06	Semi-Annually	12	1.81%
ROSSELLIND.NS	No Dividend Player	2023-07-20	Sporadic	12	0.12%
LFIC.NS	Dividend Junior	2023-08-01	Annually	15	1.73%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.125	1.500	7.51	10.00	[0 - 0.5]
returnOnAssetsTTM	0	1.200	0	0	[0 - 0.3]
returnOnEquityTTM	0.163	1.500	9.30	10.00	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	0	0.800	-5.00	-4.00	[1 - 3]
quickRatioTTM	0	0.800	-4.71	-3.76	[0.8 - 2.5]
cashRatioTTM	0	1.500	-1.111	-1.667	[0.2 - 2]
debtRatioTTM	0	-1.500	0	0	[0 - 0.6]
interestCoverageTTM	18.58	1.000	4.23	4.23	[3 - 30]
operatingCashFlowPerShareTTM	49.21	2.00	10.00	10.00	[0 - 30]
freeCashFlowPerShareTTM	49.21	2.00	10.00	10.00	[0 - 20]
debtEquityRatioTTM	0	-1.500	0	0	[0 - 2.5]
grossProfitMarginTTM	0.597	1.000	3.38	3.38	[0.2 - 0.8]
operatingProfitMarginTTM	0.168	1.000	8.63	8.63	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0	1.000	-1.111	-1.111	[0.2 - 2]
assetTurnoverTTM	0	0.800	-3.33	-2.67	[0.5 - 2]
Total Score				3.90

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	37.32	1.000	6.33	0	[1 - 100]
returnOnEquityTTM	0.163	2.50	9.55	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	49.21	2.00	10.00	10.00	[0 - 30]
dividendYielPercentageTTM	0.916	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	49.21	2.00	10.00	10.00	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	9.78	1.500	10.00	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.0466	1.000	-1.336	0	[0.1 - 0.5]
Total Score				5.50

Alkem Laboratories

Alkem Laboratories Limited, a pharmaceutical company, engages in the development, manufacture, and sale of pharmaceutical and nutraceutical products in India and internationally. The company offers branded generics, generic drugs, active pharmaceutical ingredients, biosimilars, and nutraceuticals in acute and chronic therapeutic areas comprising anti-infective, dermatology, cardiac, respiratory, gastro-intestinal, central nervous system, oncology, urology, and gynaecology, as well as vitamins, minerals, and nutrients; and pain analgesic, anti-diabetic, and neurology products. It also provides pregnancy detection kits and condoms. The company was incorporated in 1973 and is headquartered in Mumbai, India.